The stunning revelation from Oscar winner, Angelina Jolie, that as a BRCA1 mutation carrier, she underwent prophylactic double mastectomy to reduce her risk of developing breast cancer, renewed widespread interest in the gene. This spring, two groups of publications based on original research by BCRF grantees, Fergus Couch, PhD
(The Mayo Clinic) and Titia de Lange, PhD
(The Rockefeller University), shed new light on BRCA1, the mutated copy of which increases an individual's risk of developing breast cancer over five-fold from 12 to 65 percent.
Building on earlier work by fellow grantee, Mary-Claire King, PhD (University of Washington) who discovered the BRCA1 gene, Dr. Couch's recent discoveries will dramatically impact clinicians' ability to stratify and individualize risk for BRCA1 mutation carriers and help women decide how they might manage their risk - be it watchful waiting, lifestyle changes, or prophylactic surgery. Dr. de Lange's findings offer insights into how potentially to circumvent resistance to therapies, including radiotherapy and PARP inhibitors, in BRCA1 associated breast cancers.
Read more about Dr. de Lange's research
Read more about Dr. Couch's research